Effects of Brexit on supply chain of medicines examined
5 December 2017
The Health Committee hears from academics, patient groups and industry on effects that Brexit could have on the supply chain of medicines, medical devices and other medical products.
- Watch Parliament TV: Brexit: the regulation of medicines, medical devices and substances of human origin
- Inquiry: Brexit – medicines, medical devices and substances of human origin
- Health Committee
Witnesses
Tuesday 5 December 2017 in the Wilson Room, Portcullis House
At 2.45pm
- Dr Andrew Grainger, Assistant Professor in Logistics and Supply Chain Management, University of Nottingham
- Richard Freudenberg, Secretary-General of the British Association of European Pharmaceutical Distributors
- Martin Sawer, Executive Director of the Healthcare Distribution Association
- Dr Jeanette Dickson, Vice President of the Faculty of Clinical Oncology, Royal College of Radiologists
At 3.45pm
- Professor Jean McHale, Professor of Healthcare Law and Director of the Centre for Health Law, Science and Policy, University of Birmingham
- Ian Bateman, Director of Quality at NHS Blood and Transplant
- Fiona Loud, Policy Director, Kidney Care UK
- Liz Carroll, Chief Executive, The Haemophilia Society
Purpose of the session
The session covers the logistics of supply chains for medicines and medical devices, the current issues that are faced, and the risks and opportunities Brexit poses for the sector. The session also discusses supply chain and customs issues for time-sensitive products, including medical radioisotopes.
The Committee is also looking at how Brexit could affect regulation of blood, tissues, cells and organs in the UK.
Further information
- Read the House of Commons Library paper on Brexit and medicines regulation
- About Parliament: Select committees
- Visiting Parliament: Watch committees
Image: iStockphoto